drugset / Trial / NCT02684136

Suvorexant in Insomnia Co-morbid With Fibromyalgia

NCT02684136

Phase 4 Terminated 10 enrolled Henry Ford Health System
RandomizedCrossoverTriple-blindTreatment

Summary

This study will compare sleep, pain and daytime sleepiness/fatigue in people with insomnia co-morbid with fibromyalgia while treated short-term with suvorexant 20 mg versus placebo.

Timeline

Start
2016-02-01
Primary completion
2018-07-01
Completion
2018-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Suvorexant Small molecule 20 mg

Indications